365 results on '"Al-Lazikani, Bissan"'
Search Results
2. SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancers
3. Probabilistic graph-based model uncovers previously unseen druggable vulnerabilities in major solid cancers
4. Supplementary Figure 7 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
5. Supplementary Figure 12 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
6. Data from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
7. Supplementary Figure 3 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
8. Supplementary Figure 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
9. Supplementary Table 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
10. Supplementary Figure 9 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
11. Supplementary Table 6 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
12. Supplementary Table 1 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
13. Supplementary Table 3 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
14. Supplementary Figure 8 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
15. Supplementary Materials and Methods from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
16. Supplementary Figure 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
17. Supplementary Figure 6 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
18. Supplementary Table 7 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
19. Supplementary Table 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
20. Supplementary Table 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
21. Supplementary Figure 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
22. canSAR chemistry registration and standardization pipeline
23. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
24. Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer.
25. Evolution of kinase polypharmacology across HSP90 drug discovery
26. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.
27. Objective, Quantitative, Data-Driven Assessment of Chemical Probes
28. Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
29. Effective Function Annotation through Catalytic Residue Conservation
30. Supplementary Figure from Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
31. Data from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
32. Supplementary Table from Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
33. Supplementary Tables S1-S4 from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
34. Supplementary Note from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
35. Supplementary Figures S1-S3 from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
36. Supplementary Data from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
37. Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches
38. The kinase polypharmacology landscape of clinical PARP inhibitors
39. Combining Multiple Structure and Sequence Alignments to Improve Sequence Detection and Alignment: Application to the SH2 Domains of Janus Kinases
40. Canonical structures of immunoglobulins and T cell receptors
41. Supplementary Figure from JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
42. Data from JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
43. Supplementary Table from JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
44. Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
45. canSAR: update to the cancer translational research and drug discovery knowledgebase
46. R-loop editing by DNA cytosine deaminase APOBEC3B determines the activity of estrogen receptor enhancers
47. The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use
48. Targeting the BAG-1 family of co-chaperones in lethal prostate cancer
49. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates
50. Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.